Find Clinical Trial

Home » Find Clinical Trials » Efficacy and safety of agomelatine with flexible dose (25 mg/day with blinded potential adjustment at 50 mg) given orally for 8 weeks in Indian outpatients with Major Depressive Disorder A randomised double-blind national multicentric study with parallel groups, versus sertraline (50 mg/day with blinded potential adjustment at 100 mg).

Efficacy and safety of agomelatine with flexible dose (25 mg/day with blinded potential adjustment at 50 mg) given orally for 8 weeks in Indian outpatients with Major Depressive Disorder A randomised double-blind national multicentric study with parallel groups, versus sertraline (50 mg/day with blinded potential adjustment at 100 mg).

← Back

Study Phase	Phase 3

Therapeutic Area	Neuropsychiatric Diseases

Indication	Major Depressive Disorder

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	AGOMELATINE, S020098

Active Substance Code	S020098

Protocol Code	CL3-20098-074

Documents and links

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.